Affordable Access

deepdyve-link deepdyve-link
Publisher Website

PPARγ agonists target aromatase via both PGE2 and BRCA1.

Authors
  • Margalit, Ofer
  • Wang, Dingzhi
  • Dubois, Raymond N
Type
Published Article
Journal
Cancer prevention research (Philadelphia, Pa.)
Publication Date
Oct 01, 2012
Volume
5
Issue
10
Pages
1169–1172
Identifiers
DOI: 10.1158/1940-6207.CAPR-12-0365
PMID: 23041473
Source
Medline
License
Unknown

Abstract

Obesity is a well-recognized risk factor for postmenopausal breast cancer. Although the underlying mechanisms are not clearly defined, aromatase is thought to play a pivotal role in connecting obesity-associated inflammation with postmenopausal breast cancer. It has been well established that both the proinflammatory prostaglandin E(2) (PGE(2)) and the BRCA1 tumor-suppressor gene regulate aromatase expression. In this issue of the journal (beginning on p. 1183), Subbaramaiah and colleagues improve our understanding of the molecular mechanisms by which PPARγ inhibits aromatase expression. They found that pioglitazone, a PPARγ agonist, inhibited aromatase expression by inhibition of PGE(2) signaling and upregulation of BRCA1. Their findings provide potential targets for preventing or treating obesity-related breast cancer.

Report this publication

Statistics

Seen <100 times